Yahoo
NYSE - Delayed Quote USD

Haemonetics Corporation (HAE)

59.26 -0.83 (-1.38%)
At close: May 1 at 4:00:03 PM EDT
58.08 -1.18 (-1.99%)
After hours: May 1 at 5:25:16 PM EDT
Trade HAE on Coinbase
Chart Range Bar
Loading chart for HAE
  • Previous Close 60.09
  • Open 60.30
  • Bid --
  • Ask --
  • Day's Range 59.24 - 60.72
  • 52 Week Range 47.32 - 87.32
  • Volume 618,682
  • Avg. Volume 809,686
  • Market Cap (intraday) 2.754B
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) 16.33
  • EPS (TTM) 3.63
  • Earnings Date May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 84.60

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

www.haemonetics.com

3,023

Full Time Employees

March 29

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview: HAE

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HAE
26.06%
S&P 500 (^GSPC)
5.62%

1-Year Return

HAE
5.92%
S&P 500 (^GSPC)
29.01%

3-Year Return

HAE
28.46%
S&P 500 (^GSPC)
73.47%

5-Year Return

HAE
11.89%
S&P 500 (^GSPC)
72.92%

Earnings Trends: HAE

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 338.97M
Earnings 61.44M

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
300M

Analyst Insights: HAE

View More

Analyst Price Targets

64.00
84.60 Average
59.26 Current
108.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/13/2026
Analyst Mizuho
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 80 -> 70

Statistics: HAE

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    2.75B

  • Enterprise Value

    3.62B

  • Trailing P/E

    16.33

  • Forward P/E

    10.87

  • PEG Ratio (5yr expected)

    0.91

  • Price/Sales (ttm)

    2.16

  • Price/Book (mrq)

    3.02

  • Enterprise Value/Revenue

    2.74

  • Enterprise Value/EBITDA

    9.94

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.31%

  • Return on Assets (ttm)

    6.45%

  • Return on Equity (ttm)

    19.30%

  • Revenue (ttm)

    1.32B

  • Net Income Avi to Common (ttm)

    175.44M

  • Diluted EPS (ttm)

    3.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    363.56M

  • Total Debt/Equity (mrq)

    134.40%

  • Levered Free Cash Flow (ttm)

    335.05M

Compare To: HAE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: HAE

Fair Value

59.26 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: HAE

View More
  • What does Argus have to say about HAE?

    Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Lowering target price to $66.00

    Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Raising target price to $67.00

    Haemonetics Corp has an Investment Rating of BUY; a target price of $67.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Raising target price to $66.00

    Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: